Outcome-Driven Personalized Treatment Design for Managing Diabetes

References

• American Diabetes Association (2018) Economic costs of diabetes in the U.S. in 2017. Diabetes Care 41(5):917–928.Crossref, Google Scholar
• Alwan N, Tuffnell DJ, West J (2009) Treatments for gestational diabetes. Cochrane Database Systems Rev. 2009(3):CD003395.Google Scholar
• Beckmann CRB, Ling FW, Barzansky BM, Herbert WNP, Laube DW, Smith RP (2013) Obstetrics and Gynecology, 7th ed. (Lippincott Williams & Wilkins, Philadelphia).Google Scholar
• Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: A systematic review and meta-analysis. Lancet 373(9677):1773–1779.Crossref, Google Scholar
• Bergman RN, Ider YZ, Bowden CR, Cobelli C (1979) Quantitative estimation of insulin sensitivity. Amer. J. Physiol. 236(6):E667–E677.Google Scholar
• Brockwell PJ, Davis RA (2006) Introduction to Time Series and Forecasting (Springer Science & Business Media, New York).Google Scholar
• Centers for Disease Control and Prevention (2017) New CDC report: More than 100 million Americans have diabetes or prediabetes (July 18). Accessed April 2, 2017, https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html.Google Scholar
• Chan P, Holford N (2001) Drug treatment effects on disease progression. Ann. Rev. Pharmacol. Toxicol. 41(1):625–659.Crossref, Google Scholar
• Chen Y, Quick WW, Yang W, Zhang Y, Baldwin A, Moran J, Moore V, Sahai N, Dall TM (2009) Cost of gestational diabetes mellitus in the United States in 2007. Population Health Management 12(3):165–174.Crossref, Google Scholar
• Cobelli C, Dalla Man C, Sparacino G, Magni L, De Nicolao G, Kovatchev BP (2009) Diabetes: Models, signals, and control. IEEE Rev. Biomedical Engrg. 2(January 1):54–96.Crossref, Google Scholar
• Derendorf H, Meibohm B (1999) Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: Concepts and perspectives. Pharmaceutical Res. 16(2):176–185.Crossref, Google Scholar
• De Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M (2006) A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J. Pharmacokinetics Pharmacodynamics 33(3):313–343.Crossref, Google Scholar
• Frey N, Laveille C, Paraire M, Francillard M, Holford N, Jochemsen R (2003) Population PKPD modelling of the long‐term hypoglycaemic effect of gliclazide given as a once‐a‐day modified release (MR) formulation. Br. J. Clin. Pharmacol. 55(2):147–157.Crossref, Google Scholar
• Gibaldi M, Perrier D (1975) Pharmacokinetics (Marcel Dekker, New York).Google Scholar
• Gillespie P, Cullinan J, O'Neill C, Dunne F, Atlantic DIP Collaborators (2013) Modeling the independent effects of gestational diabetes mellitus on maternity care and costs. Diabetes Care 36(5):1111–1116.Crossref, Google Scholar
• Hawkins JS, Casey BM, Lo JY, Moss K, McIntire DD, Leveno KJ (2009) Weekly compared with daily blood glucose monitoring in women with diet-treated gestational diabetes. Obstetrics Gynecol. 113(6):1307–1312.Crossref, Google Scholar
• Hill AV (1910) The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol. 40(January):4–7.Google Scholar
• Hill AV (1913) The combinations of haemoglobin with oxygen and with carbon monoxide. Biochemical J. 7(5):471–480.Crossref, Google Scholar
• Hillier TA, Vesco KK, Pedula KL, Beil TL, Whitlock EP, Pettitt DJ (2008) Screening for gestational diabetes mellitus: A systematic review for the U.S. preventive services task force. Ann. Internal Med. 48(10):766–775.Crossref, Google Scholar
• Holford NH, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol. Therap. 16(2):143–166.Crossref, Google Scholar
• Jacqueminet S, Jannot-Lamotte MF (2010) Therapeutic management of gestational diabetes. Diabetes Metab. 36(December):658–671.Crossref, Google Scholar
• Jovanovic L, Pettitt DJ (2001) Gestational diabetes mellitus. JAMA 286(20):2516–2518.Crossref, Google Scholar
• Jovanovic-Peterson L, Durak EP, Peterson CM (1989) Randomized trial of diet vs. diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Amer. J. Obstetrics Gynecol. 161(2):415–419.Crossref, Google Scholar
• Kim C (2010) Gestational diabetes: Risks, management, and treatment options. Internat. J. Women’s Health 2:339–351.Crossref, Google Scholar
• Kimber-Trojnar Z, Marciniak B, Leszczyńska-Gorzelak B, Trojnar M, Oleszczuk J (2008) Glyburide for the treatment of gestational diabetes mellitus. Pharmacol. Rep. 60(3):308–318.Google Scholar
• Landersdorfer CB, Jusko WJ (2008) Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus. Clin. Pharmacokinetics 47(7):417–448.Crossref, Google Scholar
• Menke A, Casagrande S, Geiss L, Cowie CC (2015) Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 314(10):1021–1029.Crossref, Google Scholar
• Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, et al. (2008) Hyperglycemia and adverse pregnancy outcomes. N. Engl. J. Med. 358(19):1991–2002.Crossref, Google Scholar
• Miyazaki M, Mukai H, Iwanaga K, Morimoto K, Kakemi M (2001) Pharmacokinetic–pharmacodynamic modelling of human insulin: Validity of pharmacological availability as a substitute for extent of bioavailability. J. Pharmacy Pharmacol. 53(9):1235–1246.Crossref, Google Scholar
• NCD Risk Factor Collaboration (2016) Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387(10027):1513–1530.Crossref, Google Scholar
• Palmer AJ, Brandt A, Gozzoli V, Weiss C, Stock H, Wenzel H (2000) Outline of a diabetes disease management model: Principles and applications. Diabetes Res. Clin. Practice 50(November):S47–S56.Crossref, Google Scholar
• Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA (2004) The CORE diabetes model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr. Med. Res. Opin. 20(August):S5–S26.Crossref, Google Scholar
• Panel A (2004) Guidelines for computer modeling of diabetes and its complications. Diabetes Care 27(9):2262–2265.Crossref, Google Scholar
• Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Therap. 25(3):358–371.Crossref, Google Scholar
• Todorova K, Palaveev O, Petkova V, Stefanova M, Dimitrova Z (2007) A pharmacoeconomical model for choice of a treatment for pregnant women with gestational diabetes. Acta Diabetol. 44(3):144–148.Crossref, Google Scholar
• Wang Q, Molenaar P, Harsh S, Freeman K, Xie J, Gold C, Rovine M, Ulbrecht J (2014) Personalized state-space modeling of glucose dynamics for type 1 diabetes using continuously monitored glucose, insulin dose, and meal intake: An extended Kalman filter approach. J. Diabetes Sci. Tech. 8(2):331–345.Crossref, Google Scholar
• World Health Organization (2013) Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. World Health Organization. Accessed August 22, 2017, http://apps.who.int/iris/bitstream/10665/85975/1/WHO_NMH_MND_13.2_eng.pdf?ua=1.Google Scholar
• World Health Organization (2016) WHO global report on diabetes. Accessed June 1, 2018, http://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf;jsessionid=2EF636D595BBC61CD12A0F61D4FBA7F4?sequence=1.Google Scholar
• Zhuo X, Zhang P, Hoerger TJ (2013) Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Amer. J. Prevent. Med. 45(3):253–261.Crossref, Google Scholar